AI chips are minting profit. Surgical AI still has a much thinner evidence base
Two numbers in today's sources deserve to be held side by side without pretending they belong to the same transaction. Samsung's preliminary guidance puts third-quarter operating profit at 107.4 trillion won, nearly nine times the year-earlier figure, as demand and prices for AI-related memory support earnings. These are projected company results, with a detailed divisional breakdown due later; they do not measure the social value delivered by every AI application. Separately, a peer-reviewed scoping review in npj Digital Surgery searched five databases and identified 3,020 records on intraoperative AI clinical decision support. Only five studies met its specific inclusion criteria: one completed feasibility study and four ongoing prospective studies or registries. That does not mean only five AI-in-surgery studies exist, and it does not show these systems are unsafe. It means the prospective clinical and ethical evidence under this review's narrow question remains early. The contrast is about timing and incentives. Markets can reward the infrastructure that makes AI possible long before clinical systems have demonstrated safety, equity, consent and real patient benefit under routine conditions. A chip supplier is not responsible for conducting every surgical trial, and clinical validation properly takes longer than a quarterly earnings report. Still, the scale of investment creates a public expectation: buyers and hospitals should demand prospective outcomes and override procedures before live recommendations influence care. The impressive profit is real as a company forecast. The patient benefit is a separate question that must be tested.
